Financial Performance - The company's operating revenue for Q3 2024 was ¥1,172,931,144.85, representing a year-over-year increase of 3.38%[2] - The net profit attributable to shareholders for Q3 2024 was ¥336,661,203.63, showing a decrease of 5.18% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥331,565,655.02, down by 3.99% year-over-year[2] - The basic earnings per share for Q3 2024 was ¥0.59, a decrease of 3.28% compared to the same period last year[4] - Total operating revenue for the first three quarters of 2024 reached ¥3,380,035,059.48, an increase of 4.25% compared to ¥3,242,497,407.54 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was ¥969,432,633.28, compared to ¥915,410,745.17 in 2023, indicating a growth of 5.90%[17] - The net profit attributable to the parent company for Q3 2024 was ¥956,174,546.82, an increase from ¥900,920,385.63 in Q3 2023, representing a growth of approximately 6.1%[18] - The total comprehensive income for Q3 2024 reached ¥969,294,287.00, compared to ¥915,998,287.10 in Q3 2023, indicating an increase of about 5.8%[18] - The basic and diluted earnings per share for Q3 2024 were both ¥1.65, up from ¥1.55 in Q3 2023, reflecting a growth of 6.5%[18] Assets and Liabilities - The total assets at the end of the reporting period were ¥11,389,469,846.36, reflecting a decrease of 1.42% from the end of the previous year[4] - The equity attributable to shareholders at the end of the reporting period was ¥8,402,371,569.16, down by 1.56% compared to the end of the previous year[4] - Total assets as of the end of the third quarter of 2024 were ¥11,389,469,846.36, slightly down from ¥11,554,058,269.37 at the end of the previous year[14] - Total liabilities as of the end of the third quarter of 2024 were ¥2,903,356,026.00, compared to ¥2,887,726,931.49 in the same period last year, showing an increase of 0.89%[14] - Non-current assets totaled ¥5,254,767,410.80, up from ¥4,941,037,667.56 in the previous year, indicating a growth of 6.35%[14] - The company's equity attributable to shareholders was ¥8,402,371,569.16, a decrease from ¥8,535,461,518.03 in the previous year[14] - The company reported a decrease in short-term borrowings to ¥253,700,475.15 from ¥343,300,545.69, a reduction of 26.16%[14] Cash Flow - The company reported a net cash flow from operating activities of ¥948,965,414.66 for the year-to-date, a slight decrease of 0.23% year-over-year[2] - Cash inflows from operating activities for the first three quarters of 2024 amounted to ¥3,754,808,838.97, compared to ¥3,608,645,364.91 in the same period of 2023, marking an increase of approximately 4.0%[19] - The net cash flow from operating activities for the first three quarters of 2024 was ¥948,965,414.66, slightly down from ¥951,113,025.41 in the first three quarters of 2023[19] - Cash outflows from investing activities totaled ¥2,400,651,358.70 in the first three quarters of 2024, compared to ¥1,599,897,102.58 in the same period of 2023, indicating a significant increase of approximately 50.1%[20] - The net cash flow from financing activities for the first three quarters of 2024 was -¥1,142,060,159.46, compared to -¥191,706,034.07 in the same period of 2023, showing a decline in cash flow[20] - The cash and cash equivalents at the end of Q3 2024 were ¥319,752,756.90, down from ¥442,045,146.47 at the end of Q3 2023, representing a decrease of about 27.7%[20] Shareholder Information - The company has a total of 32,634 common shareholders at the end of the reporting period[7] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., holds 56.70% of the shares[7] - The controlling shareholder, Antu Industrial Group, increased its shareholding by 0.50% due to a reduction in total share capital[9] - As of the end of the reporting period, the company had repurchased 8,891,492 shares, accounting for 1.53% of the total share capital[9] - The company announced a share buyback plan, with Antu Industrial having already acquired 5,541,300 shares, representing 0.95% of the total share capital[10] Non-Recurring Gains and Losses - Non-recurring gains and losses for the current period totaled ¥5,095,548.61, with government subsidies contributing ¥11,086,646.32[5] Research and Development - Research and development expenses for the first three quarters of 2024 amounted to ¥511,265,272.32, an increase from ¥461,553,959.80 in the previous year, representing an increase of 10.75%[17] Inventory and Receivables - Accounts receivable increased to RMB 1,224,124,243.89 from RMB 1,153,256,246.40, reflecting a growth of approximately 6.2%[12] - Inventory rose to RMB 931,110,862.72, up from RMB 778,288,488.44, marking an increase of around 19.6%[12] Fixed Assets - The company reported a significant increase in fixed assets, which rose to RMB 3,015,555,885.87 from RMB 2,253,588,682.87, indicating a growth of about 33.8%[12] - The company's total non-current assets increased to RMB 4,192,000,000.00 from RMB 3,865,000,000.00, showing a growth of approximately 8.5%[12] - The company's long-term equity investments increased to RMB 13,434,149.16 from RMB 7,422,109.63, reflecting a growth of approximately 81.5%[12] Accounting Standards - The company did not apply new accounting standards or interpretations that would affect the financial statements for the year of first implementation[21]

第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》） 和其他有关规定，制定郑州安图生物工程股份有限公司（以下简称"公司"或"本公司"） 章程（以下简称"章程"或"本章程"）。 第二条 公司系依照《公司法》和其他有关规定成立的股份有限公司。根据《公司法》的规 定，公司采用发起方式设立，由郑州安图绿科生物工程有限公司进行整体变更，并由全体原 股东作为发起人认购公司发行的全部股份。公司于 2012 年 12 月 20 日在河南省工商行政管 理局注册登记，取得《企业法人营业执照》，注册号为 914100007167932103。 郑州安图生物工程股份有限公司 章 程 二〇二四年十月 | 第一章 总 | 则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 3 | | 第一节 | 股份发行 | 3 | | 第二节 | 股份增减和回购 | 4 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 | 6 ...

郑州安图生物工程股份有限公司 子公司管理制度 郑州安图生物工程股份有限公司 子公司管理制度 （2024 年 10 月修订） 第一章 总则 第一条 为加强郑州安图生物工程股份有限公司（以下简称"公司"）对子公司 的管理控制，确保子公司规范、高效、有序的运作，切实保护投资者利益，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《上海证券交易所股票上市规则》 （以下简称"《上市规则》"）、《上海证券交易所上市公司自律监管指引第 1 号— —规范运作》等法律法规以及《郑州安图生物工程股份有限公司章程》（以下简称"《公 司章程》"）等规定，结合公司的实际情况，制定本制度。 第二条 本制度所称的子公司是指根据公司总体发展战略规划、产业结构调整或 市场业务需要而依法投资或设立的具有独立法人资格主体的组织。子公司的设立形式 主要包括： （1） 独资设立的全资子公司； 第五条 公司主要通过向子公司委派董事、监事、高级管理人员和日常监管两条 途径行使股东权利，并主要从人事、经营决策、财务、资金、担保、投资、信息披露、 审计与考核等方面对子公司进行管理。 第六条 子公司应当加强自律性管理，并自觉接受公司检查与监督；对公司提 ...

郑州安图生物工程股份有限公司 独立董事候选人声明与承诺 本人祁园明，已充分了解并同意由提名人郑州安图生物工程股份有限公司董 事会提名为郑州安图生物工程股份有限公司第五届董事会独立董事候选人。本人 公开声明，本人具备独立董事任职资格，保证不存在任何影响本人担任郑州安图 生物工程股份有限公司独立董事独立性的关系，具体声明并承诺如下： 一、本人具备上市公司运作的基本知识，熟悉相关法律、行政法规、部门规 章及其他规范性文件，具有 5 年以上法律、经济、会计、财务、管理或者其他履 行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及公司规章的要求： （一）《中华人民共和国公司法》关于董事任职资格的规定； （二）《中华人民共和国公务员法》关于公务员兼任职务的规定； （三）中国证监会《上市公司独立董事管理办法》、上海证券交易所自律监 管规则以及公司章程有关独立董事任职资格和条件的相关规定； （四）中共中央纪委、中共中央组织部《关于规范中管干部辞去公职或者退 （离）休后担任上市公司、基金管理公司独立董事、独立监事的通知》的规定； （十）其他法律法规、部门规章、规范性文件和上海证券交易所规定的 ...

Financial Performance - The company reported a revenue of 500 million RMB for the first half of 2024, representing a 15% increase compared to the same period last year[13]. - The company expects a revenue guidance of 1.1 billion RMB for the full year 2024, indicating a projected growth of 10% year-over-year[13]. - The company's operating revenue for the first half of 2024 was approximately CNY 2.21 billion, representing a 4.70% increase compared to the same period last year[19]. - The net profit attributable to shareholders for the first half of 2024 was approximately CNY 619.51 million, an increase of 13.49% year-over-year[19]. - The basic earnings per share for the first half of 2024 was CNY 1.09, reflecting a 15.96% increase compared to the same period last year[20]. - The total profit for the first half of 2024 was ¥687,185,556.26, up from ¥608,705,140.73 in the same period last year, indicating a growth of around 12.91%[136]. - The total comprehensive income for the first half of 2024 was ¥627,047,484.45, compared to ¥555,917,473.38 in the same period of 2023, reflecting an increase of about 12.81%[137]. Research and Development - The company is investing 50 million RMB in R&D for new technologies aimed at enhancing diagnostic capabilities over the next two years[13]. - The company has a total of 1,852 R&D personnel, accounting for 33.27% of the total workforce, with 91.95% holding a bachelor's degree or higher[43]. - R&D investments from 2021 to 2023 were CNY 485.95 million, CNY 571.69 million, and CNY 656.13 million, representing 12.90%, 12.87%, and 14.77% of revenue respectively[43]. - The company's R&D investment in the first half of 2024 was 333.23 million yuan, representing 15.10% of its revenue, with a total of 1,575 patents obtained, including 60 international patents[65]. - The company emphasizes the development of core materials, achieving self-sufficiency in key raw materials such as antigens and antibodies, ensuring stable and safe supply[44]. Market Expansion and Strategy - Market expansion plans include entering three new provinces in China by the end of 2024, targeting a 25% increase in market share[13]. - The company has completed the acquisition of a local biotech firm for 200 million RMB, which is expected to enhance its product portfolio and R&D capabilities[13]. - The company has established strategic partnerships with two leading hospitals to enhance product testing and validation processes[13]. - The company has expanded its international market presence, entering regions such as the Middle East, Asia, Europe, America, and Africa[41]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the market[148]. Environmental and Social Responsibility - The wastewater treatment station has a capacity of 500m³/d, with a total wastewater discharge of 45,989.765 tons from January 1, 2024, to June 30, 2024, and a COD average discharge concentration of 31.69 mg/L, totaling 1.4387 tons[85]. - The company has implemented a comprehensive environmental monitoring plan, conducting bi-monthly tests on wastewater pollutants and regular third-party monitoring of various emissions[88]. - The company established the "Antu Forward Scholarship" in 25 universities, benefiting nearly 2,000 students by the end of the reporting period[92]. - The company has provided cash assistance of 5,000 yuan per year to over 762 veterans for seven consecutive years, with donations for 130 veterans completed by August 1, 2024[92]. Financial Position and Assets - The total assets at the end of the reporting period were approximately CNY 11.04 billion, down 4.47% from the end of the previous year[19]. - The net cash flow from operating activities decreased by 7.63% to approximately CNY 495.49 million compared to the previous year[19]. - The total assets as of June 30, 2024, amounted to CNY 11,037,702,754.60, a decrease from CNY 11,554,058,269.37 at the end of 2023, reflecting a decline of approximately 4.46%[130]. - Cash and cash equivalents decreased significantly from CNY 1,486,484,992.75 to CNY 350,141,918.49, representing a decline of about 76.4%[130]. - The total equity attributable to the parent company as of June 30, 2024, is RMB 8,535,461,518.03, a decrease of RMB 301,834 compared to the beginning of the year[146]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[5]. - The company faces risks from industry policy changes, which could adversely affect its operations if it fails to adapt to new regulations[79]. - The external diagnostic industry is experiencing rapid growth, but increased competition from both domestic and international companies poses a market risk[79]. Product Development and Offerings - New product launches include a diagnostic kit that has shown a 95% accuracy rate in clinical trials, expected to be commercially available by Q3 2024[13]. - The company offers a comprehensive range of products, including enzyme-linked immunoassay reagents and fully automated biochemical analyzers[30]. - The company has developed 60 quality control products and holds 90 national secondary standard material certificates, ensuring quality assurance for clinical laboratories[56]. - The immunological testing solutions include 331 registered products and 207 EU CE certified products, with a focus on low-cost, high-throughput solutions for clinical hospitals and independent laboratories[48]. Shareholder and Governance - Major shareholders are required to announce any share reductions three trading days in advance and complete them within six months[94]. - The company has commitments from major shareholders to limit share transfers to no more than 25% of their holdings annually during their tenure and 50% within 12 months after leaving[94]. - The company’s board and senior management have committed to measures to mitigate the dilution of immediate returns from convertible bond issuance[99]. - The controlling shareholder has promised to resolve any potential competition issues with the company by granting the company priority rights to acquire projects under certain conditions[102].

安图生物23年报及24一季报交流240419原文 2024年04月19日11:36 发言人100:00 防二道贩子搬运转卖 发言人200:24 设运转卖， 昨天晚上公司的这个财报发布出来之后，相信大家的关注度非常高。我们可以看到2023年，公司的业绩 非常平稳。2024年的一季度的业绩，应该是比大家想象的要更好一些。所以今天我们也请公司两位领导 来跟各位交流一下公司的这个经营状态，以及对2024年全年的一个展望。今天的交流，首先请黄总跟各 位介绍一下年报以及一报的一个业绩经营情况。后面接下来请与会的各家券商分析师老师先跟向公司管 理层提问。最后再如果有没有时间的话，请线上投资者提问。好的，方总，首先请您大概介绍一下业绩 情况。 发言人301:42 好的，各位投资者，各位家长朋友，大家早早上好。业绩的一年报和一季报的经营情况，我估计大家都 看到了。去年的收入去年那个收入和利润，今年的收入，一季报的利润和收入都大家都知道了，我就不 再耽误大家时间，我把可能个别代理，个别很个别投资者没有看到我们的今天那个就是几个拆分情况。 发言人302:06 更多内容关注” 搬运转卖， 发言人302:23 核酸点的实际是1740万 ...

Financial Performance - The company's operating revenue for 2023 was approximately CNY 4.44 billion, a slight increase of 0.05% compared to CNY 4.44 billion in 2022 [21]. - The net profit attributable to shareholders for 2023 was approximately CNY 1.22 billion, representing a growth of 4.28% from CNY 1.17 billion in 2022 [21]. - The net profit after deducting non-recurring gains and losses was approximately CNY 1.19 billion, up 5.86% from CNY 1.12 billion in 2022 [21]. - The company's total assets increased by 10.33% to approximately CNY 11.55 billion at the end of 2023, compared to CNY 10.47 billion at the end of 2022 [21]. - The net assets attributable to shareholders rose by 9.67% to approximately CNY 8.54 billion at the end of 2023, compared to CNY 7.78 billion at the end of 2022 [21]. - The basic earnings per share for 2023 was CNY 2.10, reflecting a 5.00% increase from CNY 2.00 in 2022 [22]. - The diluted earnings per share for 2023 was also CNY 2.10, consistent with the basic earnings per share [22]. - The company reported a net cash flow from operating activities of approximately CNY 1.47 billion in 2023, a decrease of 5.68% from CNY 1.56 billion in 2022 [21]. - The company achieved a revenue of 4.444 billion RMB in 2023, representing a year-on-year growth of 0.05%, and a growth of approximately 16.64% after excluding COVID-19 testing-related income [31]. - The company reported a 12.97% decrease in operating costs, amounting to CNY 1,552.25 million, compared to the previous year [80]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 10.50 per 10 shares, totaling RMB 608,800,611.30, which represents 50.01% of the net profit attributable to shareholders for the reporting period [4]. - The total share capital for dividend distribution is calculated based on 579,810,106 shares after deducting repurchased shares [4]. - The company does not plan to issue new shares or convert capital reserves into share capital during this dividend distribution [4]. - The company's profit distribution policy emphasizes cash dividends over stock dividends, with a minimum cash dividend ratio of 20% of the distributable profit [163]. - In mature stages without significant capital expenditure, the minimum cash dividend ratio is set at 80% [164]. - The company will review its shareholder return plan every three years, considering feedback from shareholders and independent directors [164]. Research and Development - Research and development investment reached 656.1304 million RMB, accounting for 14.77% of total revenue [31]. - The company obtained 60 new product registration certificates during the reporting period, covering various testing methods and enhancing its product portfolio [31]. - The company established dual R&D centers in Zhengzhou and Shanghai to advance the domestic production of gene sequencing technology [33]. - The company has developed multiple mass spectrometry systems and is expanding applications in nucleic acid testing and drug sensitivity testing [33]. - The company has a total of 1,419 patents, including 60 international patents, and has participated in the formulation of 101 industry standards [31]. - The company has established a high-quality R&D team with 1,823 personnel, accounting for 32.91% of total employees, and 91.66% of R&D staff hold at least a bachelor's degree [56]. - R&D investment from 2021 to 2023 was 485.95 million, 571.69 million, and 656.13 million CNY, representing 12.90%, 12.87%, and 14.77% of revenue respectively [56]. Market and Industry Trends - The global in vitro diagnostic (IVD) market is projected to reach approximately $106.26 billion in 2023, with a forecasted growth to $128.2 billion by 2028 [37]. - The IVD market is experiencing a growth rate of 10.4% from 2023 to 2028, driven by advancements in automation and strategic collaborations among companies [37]. - The IVD industry is rapidly evolving, with molecular diagnostics being the fastest-growing sub-sector, particularly in applications for infectious diseases and genetic testing [38]. - The Chinese government is actively promoting the in vitro diagnostic industry through policies and funding, with high-performance medical devices identified as a key development area in the "14th Five-Year Plan" [41]. - The domestic in vitro diagnostic industry is transitioning from a nurturing phase to a rapid growth phase, attracting numerous competitors [122]. Corporate Governance - The company has established a robust governance structure, ensuring compliance with relevant laws and regulations to maximize shareholder interests [124]. - The controlling shareholder, Antu Industrial, maintains independence in personnel, finance, and operations, adhering to regulatory requirements [125]. - The annual shareholders' meeting on May 11, 2023, approved 10 proposals without any rejections [126]. - The board of directors and management team have shown a commitment to their responsibilities, with significant shareholding changes reported among key executives [130]. - The company has a clear strategy for maintaining operational independence from its controlling shareholder, ensuring compliance with industry regulations [125]. - The company has established principles for related party transactions, ensuring pricing is based on market principles and fair disclosure practices are followed [192]. Environmental Responsibility - The company invested 13.6532 million yuan in environmental protection during the reporting period [172]. - The wastewater treatment plant has a capacity of 500m3/d, with a total wastewater discharge of 113,155.647 tons in 2023, and an average COD discharge concentration of 31.75 mg/L [173]. - The company has established a real-time monitoring system for wastewater discharge, ensuring compliance with environmental standards [173]. - The company has received ISO14001 environmental management system certification, indicating a commitment to environmental protection [181]. - The company actively responds to government pollution control initiatives by installing an environmental logistics access system and monitoring pollution control equipment [182]. Strategic Partnerships and Market Expansion - The company is actively expanding into international markets, with a restructured trade and cooperation framework to enhance market presence [53]. - The company is exploring partnerships to enhance distribution channels and improve market penetration [133]. - The company plans to expand its product line in point-of-care testing (POCT) to meet the growing demand in grassroots medical units [75]. - The company is committed to continuous innovation and market expansion to meet the increasing demand for diagnostic solutions [103]. Risk Management - The company has outlined various risks and corresponding countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks [7]. - The company recognizes the risk of market competition, particularly from international companies dominating the high-end market [122]. - The company faces risks from industry policy changes, which could impact production and operations if not adapted to new regulations [121]. - The company is focused on continuous product and technology development to keep pace with industry advancements and mitigate technology iteration risks [122].

Financial Performance - The company's operating revenue for Q1 2024 was ¥1,089,195,256.05, representing a year-on-year increase of 5.09%[4] - The net profit attributable to shareholders was ¥324,212,004.34, reflecting a significant increase of 33.93% compared to the same period last year[4] - The net cash flow from operating activities reached ¥328,402,122.27, marking a substantial increase of 61.21% year-on-year[4] - Basic earnings per share (EPS) for the period was ¥0.56, which is an increase of 33.33% compared to the previous year[5] - The operating profit for Q1 2024 was ¥363,984,360.14, compared to ¥270,901,472.75 in Q1 2023, indicating an increase of approximately 34.3%[19] - The net profit for Q1 2024 reached ¥328,699,468.29, up from ¥247,172,878.22 in Q1 2023, marking a growth of around 32.9%[20] - The total comprehensive income for Q1 2024 was ¥328,712,789.76, compared to ¥247,052,244.69 in Q1 2023, showing an increase of approximately 32.9%[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥11,605,922,648.81, showing a slight increase of 0.45% from the end of the previous year[5] - The total liabilities decreased to ¥2,752,063,672.66 in Q1 2024 from ¥2,887,726,931.49 in Q1 2023, a reduction of approximately 4.7%[19] - The total assets reached approximately CNY 11.61 billion, compared to CNY 11.55 billion at the end of 2023, marking an increase of about 0.4%[16] - The short-term borrowings decreased to approximately CNY 244.08 million from CNY 343.30 million, a reduction of about 29%[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 22,419[9] - The largest shareholder, Zhengzhou Antu Industrial Group Co., Ltd., held 55.25% of the shares[9] - The major shareholder, Zhengzhou Antu Industrial Group, holds 55.25% of the total shares, with no significant changes in shareholding structure reported[13] Cash Flow and Investments - In Q1 2024, the company reported cash inflows from operating activities of approximately $1.33 billion, an increase of 11.6% compared to $1.19 billion in Q1 2023[21] - The net cash flow from operating activities was $328.4 million, up from $203.7 million in the same period last year, representing a growth of 61.3%[21] - Cash outflows from investing activities totaled approximately $863.4 million, compared to $614.6 million in Q1 2023, indicating a 40.5% increase[22] - The net cash flow from investing activities was negative at $622.98 million, slightly worse than the negative $587.69 million reported in Q1 2023[22] - Cash inflows from financing activities amounted to $579.2 million, an increase from $365 million in Q1 2023, reflecting a growth of 58.7%[22] - The net cash flow from financing activities was negative at $113.19 million, compared to a smaller negative of $23.34 million in the previous year[22] Operational Costs and Expenses - The total operating costs decreased to ¥777,943,233.44 in Q1 2024 from ¥785,646,662.30 in Q1 2023, reflecting a reduction of about 1.0%[19] - Research and development expenses for Q1 2024 were ¥151,149,747.29, slightly down from ¥152,423,398.43 in Q1 2023, indicating a decrease of approximately 0.8%[19] - The company paid $434.31 million in employee compensation, up from $407.80 million in the same quarter last year, reflecting a rise of 6.5%[21] - The company reported a decrease in tax payments to $109.47 million from $137.54 million in Q1 2023, a reduction of 20.4%[21] Other Notable Information - The company reported a non-recurring gain of ¥10,206,805.99 for the period[7] - The company has not indicated any new product launches or significant market expansion strategies during this reporting period[14] - The cash and cash equivalents decreased to approximately CNY 1.08 billion from CNY 1.49 billion year-over-year, representing a decline of about 27.4%[15] - The accounts receivable stood at approximately CNY 1.11 billion, down from CNY 1.15 billion, indicating a decrease of about 4.3%[15] - Inventory increased to approximately CNY 833.39 million, up from CNY 778.29 million, reflecting a growth of about 7.1%[15]

证券代码：603658 证券简称：安图生物 公告编号：2023-050 郑州安图生物工程股份有限公司 关于获得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 郑州安图生物工程股份有限公司（以下简称"公司"或"安图生物"）于近日收 到河南省药品监督管理局颁发的医疗器械注册证，具体如下： | 编 | | | 注册 | | | --- | --- | --- | --- | --- | | 号 | 产品名称 | 注册证编号 | 证有 | 预期用途 | | | | | 效期 | | | 1 | D-二聚体检测试剂盒（化学 | 豫械注准 | 5 年 | 本产品用于体外定量检测人血 | | | 发光微粒子免疫检测法） | 20232400836 | | 浆或全血中 D-二聚体的含量。 | | | 中性粒细胞明胶酶相关脂质 | | | 本产品用于体外定量检测人尿 | | 2 | 运载蛋白检测试剂盒（化学 | 豫械注准 | 年 5 | 液中的中性粒细胞明胶酶相关 | | | 发光微粒子免疫检测法） | 202324008 ...

证券代码：603658 证券简称：安图生物 公告编号：2023-049 郑州安图生物工程股份有限公司 关于召开 2023 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 郑州安图生物工程股份有限公司（以下简称"公司"）已于 2023 年 10 月 26 日发布公司 2023 年第三季度报告，为便于广大投资者更全面深入地了解公司 2023 年前三季度经营成果、财务状况，公司计划于 2023 年 11 月 13 日下午 15:00-16:00 举行 2023 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年前三季度的经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的 范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 11 月 13 日 下午 15:00-16:00 三、 参加人员 公司董事长苗拥军先生，董事兼财务总监冯超姐女士， ...